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Abstract The objective of this study is to identify prog-
nostic factors of treatment response to atomoxetine in
improvement of health-related quality of life (HR-QoL),
measured by the Child Health and Illness Profile-Child
Edition Parent Report Form (CHIP-CE PRF) Achievement
and Risk Avoidance domains, in children and adolescents
with attention-deficit/hyperactivity disorder (ADHD).
Pooled data from 3 placebo-controlled trials and separate
data from 3 open-label trials of atomoxetine in children and
adolescents with ADHD were analyzed using logistic
regression methods. Based on baseline impairment in the
Achievement and/or Risk Avoidance domains (CHIP-CE
PRF \ 40 points), 2 subsamples of subjects were included.
Treatment outcome was categorized as \5 points or C5
points increase in the CHIP-CE PRF Achievement and
Risk Avoidance domains. Data of 190 and 183 subjects
from the pooled sample, and 422 and 355 subjects from the
open-label trials were included in the analysis of
Achievement and Risk Avoidance domains. Baseline
CHIP-CE subdomain scores proved to be the most robust
prognostic factors for treatment outcome in both domains,
based on data from the pooled sample of double-blind
studies and from the individual open-label studies (odds
ratios [OR] 0.74–1.56, p \ 0.05; OR \ 1, indicating a
worse baseline score associated with worse odds of
responding). Initial treatment response (C25 % reduction
in ADHD Rating Scale scores in the first 4–6 weeks) was
another robust prognostic factor, based on data from the
open-label studies (OR 2.99–6.19, p \ 0.05). Baseline
impairment in HR-QoL and initial treatment response can
be early prognostic factors of atomoxetine treatment out-
come in HR-QoL in children and adolescents with ADHD.
Keywords ADHD  Health-related quality of life 
Atomoxetine  CHIP-CE  Response prediction
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
chronic neurodevelopmental disorder with core symptoms
of inattention, hyperactivity, and impulsivity. ADHD is
associated with significant impairment of cognitive, emo-
tional, and psychosocial functioning (i.e., self-esteem, aca-
demic performance, and social acceptance, parent–child and
family relationships), which goes beyond the core symptoms
and has a strong impact on the patient’s health-related
quality of life (HR-QoL) (Barkley 2002; Riley et al. 2006a;
Escobar et al. 2005). HR-QoL is a concept that measures
subjective perception of well-being in terms of physical,
mental, and social domains (i.e., broader functioning), in
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addition to disease symptoms or treatment side effects. It is
also a patient-centric (rather than clinician-centric) assess-
ment (Escobar et al. 2010). For child or adolescent patients
with ADHD, this is usually accomplished by measuring
parents’ perceptions of the child’s well-being, although it is
still considered to be more patient-centric than assessments
by clinicians or biomedical measures.
Effective pharmacotherapeutic tools already exist for the
treatment of ADHD (Nutt et al. 2007). Psychostimulants
(Jensen et al. 2001) and atomoxetine are widely used and
are recommended treatments for children and adolescents
with ADHD (Cheng et al. 2007). The efficacy and tolera-
bility of atomoxetine have already been demonstrated in a
number of randomized, placebo-controlled trials (Michel-
son et al. 2001, 2002; Spencer et al. 2002) among children
and adolescents. In addition, another body of literature
reported on improvement of emotional well-being and HR-
QoL in children and adolescents treated with atomoxetine
(Michelson et al. 2001; Prasad et al. 2007), making ato-
moxetine the most extensively studied ADHD medication
in terms of HR-QoL (Coghill 2010).
The Child Health and Illness Profile-Child Edition
(CHIP-CE) (Riley et al. 2001) is a generic HR-QoL ques-
tionnaire covering 5 domains (Satisfaction, Comfort, Risk
Avoidance, Resilience, and Achievement) and 12 subdo-
mains (see Table 1). A pooled analysis of 5 non-US ato-
moxetine trials (N = 794) (Escobar et al. 2010) and a pan-
European naturalistic study (Riley et al. 2006a), in which
the CHIP-CE (Riley et al. 2001) was used for the assess-
ment of HR-QoL, showed that the most severe and con-
sistent baseline impairment in HR-QoL was present in the
Achievement and Risk Avoidance domains (see Table 1).
Additionally, based on the results of the pooled analysis,
atomoxetine was predominantly effective in improving HR-
QoL in the Achievement and Risk Avoidance domains
(effect sizes 0.4 and 0.5, respectively) (Escobar et al. 2010).
Identification of prognostic factors of treatment response
(e.g., HR-QoL criteria, biomarkers, neuroimaging) would
be essential to individualize the optimal treatment for
ADHD. Currently, there is a paucity of information about
such possible factors of treatment response for ADHD
medications in terms of improving HR-QoL.
The objective of this analysis was first to identify
prognostic factors for treatment response to atomoxetine
with regard to the improvement of HR-QoL, as measured
by the CHIP-CE Achievement and Risk Avoidance
domains, based on a pooled analysis of 3 placebo-con-
trolled clinical atomoxetine trials conducted in children and
adolescents with ADHD.
The secondary objective was to test whether the prog-
nostic factors identified above were also predictive of
response in further 3 open-label atomoxetine trials in
children and adolescents with ADHD.
Methods
Studies included in the analysis
Pooled patient-level data from 3 double-blind, randomized,
placebo-controlled trials and separate data from 3 open-
label trials with similar inclusion and exclusion criteria
were included in this analysis (Dickson et al. 2007; Prasad
et al. 2007; Dell’Agnello et al. 2009; Escobar et al. 2009;
Svanborg et al. 2009; Fuentes et al. 2010). A total of 1,192
Table 1 Child Health and Illness Profile-Child Edition—Parent
Report Form (CHIP-CE PRF) domain and subdomain definitions




Satisfaction domain The parent’s assessment of the child’s sense
of well-being and self-esteem (11 items)
Satisfaction with
health
Overall perceptions of well-being and health
Satisfaction with self General self-concept
Comfort domain Parent’s assessment of the child’s
experience of physical and emotional
symptoms and positive health sensations
and observed limitations of activity (22
items)
Physical comfort Positive and negative somatic feelings and
symptoms
Emotional comfort Positive and negative emotional feelings
and symptoms
Restricted activity Restrictions in day-to-day activities due to
illness
Resilience domain Parent’s perception of the child’s
participation in family, coping abilities,
and physical activity (19 items)




Active approaches to solving an
interpersonal problem




Degree to which parent perceives that the
child avoids behaviors that increase the




Avoidance of activities that threaten
individual health and development
Threats to
achievement
Avoidance of behaviors that typically
disrupt social development
Achievement domain Extent to which the parent perceives that the
child meets expectations for role




School performance and engagement
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patients were included in these studies. Design, sample
size, and duration of the studies are described in Table 2.
Only non-US studies from the Lilly database were
included, where a HR-QoL measure was used as primary/
secondary objective, CHIP-CE was employed, main find-
ings have been published, and data were available. These
studies all had very similar designs, and all used the same
HR-QoL outcome measures.
All included patients met the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV-TR)
(American Psychiatric Association 2000) diagnostic crite-
ria for ADHD and had a symptom severity of at least 1.5
standard deviations (SDs) above the normative values of
the Attention-Deficit/Hyperactivity Disorder Rating Scale–
IV (ADHD-RS), Parent Version (DuPaul et al. 1998).
The following differences among the studies were
noted:
Study 3, however, applied the ADHD subscale of the
Swanson, Nolan, and Pelham-IV (SNAP-IV) (Swanson 1992).
In all studies with the exception of Study 5, the diag-
nosis was confirmed by the Kiddie Schedule for Affective
Disorders and Schizophrenia for School Age Children-
Present and Lifetime Version (K-SADS-PL) (Kaufman
et al. 1997). The K-SADS-PL was also used for the
assessment of comorbid psychiatric disorders (except for
Study 3, in which SNAP-IV was applied for the evaluation
of comorbid oppositional defiant disorder).
In Studies 2, 3, and 6, a baseline Clinical Global
Impression of Severity (CGI-S) (Guy 1976) score of C4
was required for inclusion.
Studies 2 and 6 included medication-naı¨ve patients only.
Study 3, which was conducted in Italy, did not explicitly
require medication-naı¨ve patients, but at the time of




This analysis was based on data assessed with the Child
Health and Illness Profile-Child Edition Parent Report
Form (CHIP-CE PRF) (Riley et al. 2001, 2006b), a 76-item
generic HR-QoL questionnaire covering 5 domains (Sat-
isfaction, Comfort, Risk Avoidance, Resilience, and
Achievement) and 12 subdomains. Table 1 summarizes
which aspects of HR-QoL are assessed by each domain and
subdomain of the CHIP-CE.
CHIP-CE scores are standardized to t scores with a
mean (±SD) of 50 (±10); higher scores indicate better
health. Recently, the CHIP-CE total score was devel-
oped—this can be used as a global measure of HR-QoL
(Riley et al. 2007).
WFIRS-P
The Weiss Functional Impairment Rating Scale-Parent
Report (WFIRS-P) measures the impact of ADHD on the
child’s functioning in multiple domains (Weiss and Weiss
2004) as rated by the parents. The 50-item WFIRS-P
consists of 6 domains related to functioning: home, school,
self-concept, social, activities of daily living, and risk
taking. The WFIRS-P was applied as an additional QoL
scale together with the CHIP-CE PRF in Studies 5 and 6
for assessing functional outcome.
Statistical analysis
Two CHIP-CE domains (Achievement and Risk Avoid-
ance) were considered in the analyses, and all analyses
were conducted separately for each domain. Response was
Table 2 Basic information
about the 6 clinical trials
included in this meta-analysis
CAN Canada, E Spain, EU
European Union, this study was
conducted in 7 European
countries (Spain, Belgium, UK,
France, Turkey, Italy, Norway),
I Italy, M Mexico, S Sweden,
UK United Kingdom
a In case of Study 6, endpoint
for this analysis was at week 16



































Dickson et al. (2007)
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74.1
Open-label, atomoxetine only 12 0.5–1.4
Study 6a (EU, M)




other early standard treatment
52 1.2–1.8
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defined as a C5 points increase from baseline to endpoint
in the domain score. We chose the 5 points improvement as
response definition because it represents a 0.5 SD change in
the CHIP-CE PRF, and a half SD difference is considered a
clinically significant change in HR-QoL in a patient
(Norman et al. 2003).
For the primary objective, data of all atomoxetine-
treated patients from the 3 placebo-controlled trials were
pooled. First, the 2 subpopulations of patients showing
impairment in the examined domains of CHIP-CE
(Achievement and Risk Avoidance) at baseline were
identified. Impairment was defined as a baseline score of
the respective domain \40. Data from the 2 subsamples
(baseline impairment in the Achievement domain and
baseline impairment in the Risk Avoidance domain) were
analyzed separately.
For the purpose of identifying prognostic factors of
treatment response to atomoxetine in the Achievement and
Risk Avoidance domains of CHIP-CE (the dependent
variables), logistic regression (binary logits) was per-
formed for both domains. Possible prognostic factors
included the following: study (membership in a certain
study pooled for analysis), ADHD subtype (combined,
hyperactive/impulsive, or inattentive), any preexisting
psychiatric disorder (any affective, any anxiety, any tic
disorders, oppositional defiant disorder/conduct disorder
[ODD/CD], other), any early (first 2 weeks) treatment-
emergent adverse events, age (subjects \12 or C12-year
old), gender, race (Caucasian vs. other), baseline CHIP-CE
subdomain scores, years since the onset of ADHD symp-
toms, ADHD-RS hyperactivity/impulsivity and inattentive
subscores (subscales of SNAP-IV for Study 3), and base-
line CGI-S. The full model was reduced by backward
selection methods (i.e., going through iterations of
excluding the least significant variable and refitting the
model thereafter) until only explanatory variables statisti-
cally significant at the 5 % level remained. Model fit was
assessed using the Hosmer–Lemeshow test (Hosmer and
Lemeshow 2000). Adjusted odds ratios (ORs) and their
95 % confidence intervals (CIs) were calculated for each of
the independent variables included in the reduced model.
For the ‘CHIP-CE PRF baseline subdomain scores’ vari-
able, ORs per -5 points are presented in order to show the
change in odds associated with a clinically relevant worse
score to ease interpretation.
For the secondary objective, the analyses above were
repeated for each of the 3 open-label studies separately;
only impaired subjects at baseline with regard to the
Achievement and/or Risk Avoidance domains were
included. In these analyses, additional independent vari-
ables were included where there were other potentially
important measures collected. In all cases, initial symp-
tomatic (treatment) response (defined as a 25 % decrease
on the ADHD-RS total score during the first 4–6 weeks of
the study) and, for Studies 5 and 6, WFIRS-P domain
scores at baseline were also included as independent
variables.
All tests of hypotheses were considered statistically
significant if the 2-sided p value was B0.05. All analyses
were done post hoc and are therefore exploratory.
Results
Patient population and disposition
The pooled sample from the 3 placebo-controlled trials
included 255 patients who were randomized to atomoxe-
tine treatment. Based on the subjects’ baseline impairment,
analyses of the Achievement domain included 190 subjects
(82.6 % male, 67.4 % \12-year old); analyses of the Risk
Avoidance domain included 183 subjects (85.2 % male,
69.9 % \12-year old).
Baseline characteristics of the samples included in the
analyses are summarized in Table 3.
Prognostic factors: pooled data of the 3
placebo-controlled trials
Achievement domain
The final model of the logistic regression included 5 vari-
ables, predicting treatment outcome with atomoxetine in the
Achievement domain: (1) study (OR 0.15; p \ 0.001; 95 %
CI 0.06–0.39, Study 3 vs. Study 1). We found that indi-
viduals who were included in Study 1 had a higher chance
of improving more than 5 points (0.5 SD) in the Achieve-
ment domain after treatment compared with those included
in Study 3, but not compared with those in Study 2
(p = 0.15); (2) Academic Performance subdomain at
baseline (OR 1.43; p = 0.002; 95 % CI 1.14–1.80); (3)
Emotional Comfort subdomain at baseline (OR 1.19;
p = 0.050; 95 % CI 1.00–1.41); (4) Peer Relations subdo-
main at baseline (OR 1.30; p = 0.002; 95 % CI 1.10–1.54);
(5) Satisfaction with Health subdomain at baseline (OR
0.78; p = 0.001; 95 % CI 0.67–0.91). These results indi-
cated that every -5 points (-0.5 SD) at baseline in the
Academic Performance, Emotional Comfort, and Peer
Relations subdomains increased the odds for improving
more than 5 points in the Achievement domain after treat-
ment. In case of the Satisfaction with Health subdomain,
results showed that the more impaired the subject was at
baseline, the less improvement could be observed in the
Achievement domain after the treatment (Fig. 1).
28 A. Montoya et al.
123
Table 3 Baseline characteristics of the samples included in the analyses
Study CHIP-CE domain Placebo-controlled studies








n (%)b 190 (74.5) 84 (80.8) 172 (77.8) 166 (83.4)
Male (%) 157 (82.6) 74 (88.1) 124 (72.1) 135 (81.3)
\12 years old (%) 128 (67.4) 53 (63.1) 172 (100) 136 (81.9)
ADHD subtype, n (%)
Combined 149 (78.4) 75 (89.3) 137 (79.7) 131 (78.9)
Hyperactive/impulsive 7 (3.7) 2 (2.8) 3 (1.7) 3 (1.8)
Inattentive 34 (17.9) 7 (8.3) 32 (18.6) 32 (19.3)
Baseline score, mean (SD)c 28.0 (7.9) 23.6 (8.5) 28.1 (7.6) 24.6 (9.9)
Endpoint score, mean (SD)c 32.6 (9.7) 34.7 (13.1) 36.6 (10.8) 33.5 (13.0)
Risk Avoidance domain
n (%)b 183 (71.8) 95 (91.3) 134 (60.6) 126 (63.3)
Male (%) 156 (85.2) 83 (87.3) 108 (80.6) 106 (84.1)
\12 years old (%) 128 (69.9) 61 (64.2) 134 (100) 104 (82.5)
ADHD subtype, n (%)
Combined 155 (84.7) 85 (89.5) 115 (85.8) 108 (85.7)
Hyperactive/impulsive 8 (4.4) 2 (2.1) 3 (2.2) 2 (1.6)
Inattentive 20 (10.9) 8 (8.4) 16 (11.9) 16 (12.7)
Baseline score, mean (SD)c 27.4 (9.6) 16.4 (15.1) 26.8 (9.8) 17.8 (15.0)
Endpoint score, mean (SD)c 34.6 (10.7) 30.1 (16.9) 37.8 (12.3) 30.3 (19.4)
ADHD attention-deficit/hyperactivity disorder, CHIP-CE PRF Child Health and Illness Profile-Child Edition Parent Report Form, SD standard
deviation
a Study population treated with atomoxetine of the respective studies
b Number of individuals in the sample with baseline impairment (CHIP-CE PRF Achievement domain/Risk Avoidance domain score \40). Rest
of the data in this table refers to the impaired sample of the respective studies



























Achievement domain outcome categories
(a) Baseline CHIP-CE PRF subdomain ascores
Satisfaction with Health
OR: 0.78; 95% CI: 0.67-0.91
Peer Relations
OR: 1.30; 95% CI: 1.10-1.54
Emotional Comfort
OR: 1.19; 95% CI: 1.00-1.41
Academic Performance

















<5 points change in the Achievement domain of CHIP-CE PRF
5 points change in the Achievement domain of CHIP-CE PRF
OR: 0.15; p<0.001;
95%CI: 0.06-0.39
Study 1 vs Study 3 
OR: 0.49; p=0.148;
95%CI: 0.19-1.29
Study 1 vs Study 2
Fig. 1 Achievement domain. a Prognostic factors found for the
improvement in the Achievement domain of CHIP-CE PRF after
atomoxetine treatment, based on pooled data of 3 double-blind
placebo-controlled studies—baseline CHIP-CE PRF subdomains and
b study (i.e., in which of the 3 original studies the subject
participated). CHIP-CE PRF Child Health and Illness Profile-Child
Edition Parent Report Form, CI confidence interval, OR odds ratio
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Risk Avoidance domain
The final logistic regression model included 2 prognostic
factors of treatment outcome with atomoxetine: (1) Satis-
faction with Self subdomain at baseline (OR 0.86;
p = 0.009; 95 % CI 0.76–0.96), indicating that the more
impaired at baseline the subject was, the less chance for
improvement could be expected in the Risk Avoidance
domain after treatment; (2) Threats to Achievement sub-
domain at baseline (OR 1.30; p = 0.002; 95 % CI
1.10–1.53), showing that the more impaired the subject was
at baseline, the higher the chance was to improve more
than 5 points in the Risk Avoidance domain after treatment
(Fig. 2).
Prognostic factors: open-label studies
Table 4 summarizes the final models by CHIP-CE PRF
outcome domains (Achievement, Risk Avoidance),
including prognostic factor variables for each study
separately.
Baseline CHIP-CE PRF and WFIRS-P subdomain
scores were shown to be prognostic factors for both
Achievement and Risk Avoidance domains. The direction
of the prediction was generally that there is a higher chance
for a better outcome when more severe baseline impair-
ment is observed (OR 1.23–1.56). However, there are
CHIP-CE PRF/WFIRS-P subdomains that showed the
opposite: CHIP-CE PRF Satisfaction with Health, Social
Problem Solving subdomains, WFIRS-P Activities of daily
living, Self-concept subscores in Study 5, and WFIRS-P
Social activities subscore in Study 6.
Among the open-label studies, initial treatment response
and age were also shown to be relatively robust prognostic
factors of HR-QoL outcome. Odds ratios for initial treat-
ment response were as follows: 3.11 with regard to the
Achievement domain (Study 5), and ranging between 2.99
and 6.19 with regard to the Risk Avoidance domain
(Studies 4 and 5, respectively); ORs for age were as fol-
lows: 1.42 for the Achievement domain in Study 5, and
0.75 and 0.71 (p \ 0.05) for the Achievement and the Risk
Avoidance domains in Study 6, respectively.
Additionally, in Study 6, gender and years since onset of
ADHD symptoms were also identified as prognostic fac-
tors. In specific, female gender and more years with ADHD
were prognostic for better improvement.
In the case of Study 5, we considered age as a continuous
variable since there were no subjects[12-year old included
in this study. In the case of Study 6, after the initial analysis,
we found that age (as a categorical variable: subjects\12 or
C12-year old) was included in the final model (OR 12.1;
95 % CI 2.5–58.6) of the Risk Avoidance domain as a
prognostic factor. To test the robustness of this finding, we
reran the analysis with age as a continuous variable for both
domains. Table 4 includes the findings of this second ana-
lysis. Based on the first analysis of Study 6 data, the model
for the Achievement domain included comorbid ODD/CD
(OR 2.85; 95 % CI 1.17–6.92) and CHIP-CE PRF Threats
to Achievement baseline score (OR 0.81; 95 % CI
0.69–0.96). Both variables disappeared from the model
during the second analysis. Age, years since onset of
ADHD, and WFIRS-P Social activities subscore were not in
the first model, but were included in the second model of the
Achievement domain. Prognostic factors included in the
final model for Risk Avoidance domain did not change after
the second analysis.
Discussion
Across the samples of double-blind and open-label studies
of atomoxetine, one common pattern was that baseline
impairment in HR-QoL (as measured by the CHIP-CE PRF
and/or WFIRS-P) could predict the outcome in Achieve-
ment and Risk Avoidance domains. Although the predic-
tive subdomains of CHIP-CE PRF/WFIRS-P were different
across studies, 2 repeating patterns could be observed.
First, more severe baseline impairment in the subdomains
of the respective outcome domain (Achievement or Risk
Avoidance) was a general prognostic factor for better
outcome. This finding is in line with expectations, since the
analyses were not controlled for the baseline scores of the
examined outcome domains themselves. Second, while in
most cases, lower baseline subdomain scores of CHIP-CE



























Risk Avoidance domain outcome categories
Baseline CHIP-CE PRF subdomain scores
Satisfaction with Self
OR: 0.86; 95% CI: 0.76-0.96
Threats to Achievement
OR: 1.30; 95% CI:1.10-1.53
P<0.05
Fig. 2 Risk Avoidance domain: Prognostic factors found for the
improvement in the Risk Avoidance domain of CHIP-CE PRF after
atomoxetine treatment, based on pooled data of 3 double-blind
placebo-controlled studies—baseline CHIP-CE PRF subdomains.
CHIP-CE PRF Child Health and Illness Profile-Child Edition Parent
Report Form, CI confidence interval, OR odds ratio
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chance for a better outcome, even having adjusted for the
effect of these subdomains, for the Satisfaction with
Health, Satisfaction with Self, and Social Problem Solving
subdomains, an opposite direction of prediction could be
observed. Specifically, lower baseline scores in these latter
subdomains (as well as in the WFIRS-P Social activities
subscore) predicted less improvement in the Achievement/
Risk Avoidance domains. We hypothesize that this finding
can be explained, at least in part, by the clinical and
empirical observation that satisfied, optimistic patients
respond better to treatment compared with those with
negative thoughts, chronic pessimistic viewpoints, and lack
of satisfaction about themselves (in regard to their condi-
tion or in general).
Another robust finding of this analysis was that in the open-
label studies (Studies 4 and 5), initial treatment response in
ADHD core symptoms predicted improvement in both
Achievement and Risk Avoidance domains. Specifically,
subjects showing at least a 25 % decrease in the ADHD-RS
score during the first 4–6 weeks of treatment had a higher
chance for improvement in the Achievement/Risk Avoidance
domains of CHIP-CE as well. This finding is in line with
findings in the literature showing consistent associations
between improvement in the core symptoms of ADHD and
improvement in QoL scores, with minimal or no time lag in
studies with both methylphenidate and atomoxetine (Coghill
2010; Weiss et al. 2010). It must be noted that HR-QoL and
core symptoms are overlapping but distinct concepts. Studies
have already demonstrated that the therapeutic response in
core symptoms does not fully explain the response with
regard to HR-QoL (Escobar et al. 2010).
Unfortunately, not all of the double-blind studies
included the variable initial treatment response, and thus, it
was impossible to use this variable as a possible prognostic
factor in the analysis of the pooled sample of the double-
blind studies.
Further findings based on pooled data from the double-
blind studies showed that those subjects who participated in
Table 4 Prognostic factors of treatment response to atomoxetine in CHIP-CE PRF Achievement and Risk Avoidance domains, based on data of
the 3 open-label trials
Study CHIP-CE PRF outcome domain Predictor OR p value 95 % CI
Study 4 Achievement domain None NA NA NA
Risk avoidance domain Initial response (yes vs. no) 2.99 0.038 1.06–8.43
Individual risk avoidancea 1.27 0.016 1.05–1.55
Study 5 Achievement domain Age (years) 1.42 0.016 1.07–1.90
Initial response (yes vs. no) 3.11 0.018 1.22–7.95
Academic performancea 1.56 0.001 1.19–2.06
Individual risk avoidancea 1.23 0.028 1.02–1.48
Physical activitya 1.52 \0.001 1.20–1.92
Satisfaction with healtha 0.74 0.018 0.58–0.95
Social problem solvinga 0.77 0.006 0.64–0.93
CGI-S at baseline 0.56 0.039 0.32–0.97
WFIRS-P activities of daily living subscoreb 0.70 0.009 1.54–0.91
WFIRS-P self-concept subscoreb 1.38 0.033 1.02–1.85
Risk Avoidance domain Race (Caucasian vs. other) 5.15 0.026 1.21–21.89
Initial response (yes vs. no) 6.19 \0.001 2.38–16.11
Study 6 Achievement domain Age (years) 0.75 0.015 0.59–0.95
Gender (male vs. female) 0.18 0.003 0.06–0.56
Years since onset of ADHD symptoms 1.47 0.002 1.16–1.86
Peer relationsa 1.28 0.004 1.08–1.52
WFIRS-P social activities subscoreb 0.70 0.008 0.53–0.91
Risk Avoidance domain Age (years) 0.71 0.017 0.54–0.94
Years since onset of ADHD symptoms 1.48 0.008 1.11–1.97
WFIRS-P social activities subscoreb 0.64 \0.001 0.50–0.81
ADHD attention-deficit/hyperactivity disorder, CGI-S Clinical Global Impression of Severity, CHIP-CE PRF Child Health and Illness Profile-
Child Edition Parent Report Form, CI confidence interval, NA not applicable, OR odds ratio, WFIRS-P Weiss Functional Impairment Rating
Scale-Parent Report
a Subdomain baseline score, OR is given by every -5 points at baseline
b Subscore at baseline. For the WFIRS-P domain scores, OR by half a standard deviation increase is presented
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Study 1 had higher chance for improvement in the
Achievement domain compared with those included in
Study 3, but not compared with those in Study 2. When
interpreting this finding, we must note that there were 2
main differences across samples of these studies. First, in
Study 3, only ADHD ? ODD patients participated; second,
Study 1 included a 4-week parental psychoeducation
intervention (2 h weekly). Both differences might be taken
into account in the background of the above finding. The
positive role of psychoeducational interventions has already
been shown in outcome measures, such as treatment
response, in children and adolescents with ADHD (Mon-
toya et al. 2011). Regarding the comorbidity with ODD, the
pertinent literature suggests that children and adolescents
with ADHD and comorbid ODD/CD show more HR-QoL
impairment (Riley et al. 2006a; Coghill 2010). Up until
now, the predictive role of comorbid ODD with ADHD in
terms of treatment outcome—either negative or positive—
has not been clarified (Ollendick et al. 2008).
In a recent publication, Wehmeier et al. (2010), using
pooled data from 5 of the 6 atomoxetine studies included in
this analysis, reported that in regard to the Risk Avoidance
domain, adolescents might benefit more from atomoxetine
treatment than children. Adolescents also showed more
clinically relevant improvement in the Achievement domain
as well. According to the authors, this difference may not
have reached statistical significance because of the small
sample size of adolescents (Wehmeier et al. 2010). Based on
our present analyses, age did not prove to be a consistent
prognostic factor of improvement either in the Achievement
or Risk Avoidance domain. The findings of our analyses
with regard to age as a possible prognostic factor are further
complicated by another finding, specifically, that in Study 6,
more years since onset of ADHD symptoms was shown to be
a prognostic factor for better improvement in both outcome
domains. One would think that older individuals have more
years since onset of ADHD symptoms. However, as was
already presented, according to the findings in Study 6,
younger subjects would benefit more from treatment with
atomoxetine with regard to HR-QoL.
To the authors’ knowledge, this analysis is the first to
directly examine possible prognostic factors for atomoxe-
tine treatment outcome with regard to HR-QoL in children
and adolescents with ADHD. Other studies have examined
the effect of quality of life in children/adolescents receiv-
ing other pharmacotherapies for ADHD, but these data
were not available to us when the atomoxetine HR-QoL
studies were designed, and those studies used other HR-
QoL instruments as well as varying study designs. None-
theless, the pool of HR-QoL data is larger for atomoxetine
than for other ADHD treatments, and we are not aware of
any other analyses like ours with those other compounds.
The role of HR-QoL in understanding disease progression
or predicting treatment outcomes is gaining greater attention.
Studies have shown a uniform pattern of change in HR-QoL
with ADHD treatment, with improvements in HR-QoL
occurring concurrent with symptom improvement in both
children/adolescents and adults (Frazier et al. 2010; Weiss
et al. 2010). Thus, HR-QoL improvement does not appear to be
a delayed response to symptom improvement with treatment.
Limitations
Our findings need to be interpreted in light of certain limita-
tions. First, although the studies included in this analysis had
similar inclusion and exclusion criteria, as well as duration
and medication doses applied, heterogeneity still appears
across studies in terms of the sample and methodology. This
makes it difficult to compare findings from the individual
studies. It must be noted, however, that none of the included
studies had been originally designed to test those specific
questions we aimed to investigate in our post hoc analysis.
Second, the pooled sample as well as the individual open-
label studies contained predominantly boys and children,
leaving only a small sample of girls and adolescents (espe-
cially adolescent girls). Finally, ADHD is a chronic disorder,
and our conclusions can only be drawn for the length of the
clinical studies, reflecting the available data.
Conclusion
This analysis used a broad approach to investigate HR-QoL
treatment outcome with atomoxetine in children and ado-
lescents with ADHD.
Based on our findings, baseline impairment in HR-QoL
domains and initial treatment response in terms of ADHD
core symptoms seem to be predictive of HR-QoL treatment
outcome with atomoxetine in the case of the Achievement
and Risk Avoidance domains, as measured by the CHIP-
CE. Studies directly targeting the identification of prog-
nostic factors of improvement in HR-QoL in children and
adolescents with ADHD are needed to help clinical prac-
titioners to make individual therapeutic decisions.
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